← All indications
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.
Subtype terms (1)
More specific conditions that are subtypes of Esophageal Neoplasms in the MeSH hierarchy.
- Esophageal Squamous Cell Carcinoma
128 drugs (47 approved, 81 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (29)
- oxaliplatin
- ferric derisomaltose
- sodium glycididazole
- endostatin
- pravastatin
- naloxone
- methylprednisolone
- gimeracil
- icosapent ethyl
- cisplatin
- nicotine
- dalteparin
- iodine
- fluorouracil
- metoclopramide
- sodium chloride
- remifentanil
- tegafur
- paclitaxel
- epinephrine
- oteracil
- rocuronium
- capecitabine
- lobaplatin
- leucovorin
- tranexamic acid
- lapatinib
- irinotecan
- bupropion
Phase 3 trials (102)
- etoposide
- rc48-adc
- esomeprazole
- diphenhydramine
- tislelizumab
- lm-302
- bevacizumab
- megestrol
- fish oil
- toripalimab
- vitamin d3
- cetirizine
- pembrolizumab
- regorafenib
- alx148
- dexamethasone
- propofol
- pertuzumab
- ak109
- trastuzumab
- lenvatinib
- sintilimab
- utidelone
- mgd013
- Filgrastim
- gastrin 17 vaccine
- nedaplatin
- gemcitabine
- docetaxel
- napabucasin
- +72 more
Phase 2 trials (367)
- tew-7197
- tesetaxel
- ky1044
- elu001
- ceritinib
- sacituzumab govitecan
- cbp-1019
- imu-131
- pegamotecan
- tqb2102
- bnt141
- emibetuzumab
- osimertinib
- obi-833
- ibi315
- cytokine induced killer cells
- shr2554
- autologous natural killer cells
- blu-222
- grt-c901
- ribociclib
- ak117
- poziotinib
- urlc10-177
- nintedanib
- mm-111
- sar408701
- brivanib alaninate
- carcinoembryonic antigen peptide 1
- hydroxychloroquine
- +337 more
Phase 1 trials (204)
- tbi-1301
- zsp1602
- cmg901
- sonidegib
- 7-hydroxystaurosporine
- pt886
- alpelisib
- kk2269
- prt1419
- bms-833923
- topotecan
- ngm120
- zm008
- qbs10072s
- ro7502175
- endostatin adenovirus
- alx2004
- torl-2-307-mab
- pnt6555
- lvgn3616
- recombinant oncolytic herpes simplex virus type 1 (r130)
- amg 910
- adct-301
- zn-c3
- dec-205/ny-eso-1 fusion protein cdx-1401
- azd8701
- lvgn6051
- tpst-1120
- ly6k, vegfr1, vegfr2
- mixed bacterial vaccine
- +174 more
Other trials (45)
- ruxolitinib
- [68ga]ga-nota-g5
- qizhu yuling
- alendronic acid
- fondaparinux sodium
- cd19 car-t cells
- autologous dendritic cells electroporated with wt1 mrna
- hydrocortisone
- [68ga]ga-dota-h2d3
- varenicline
- pegulicianine
- 89zr-trastuzumab
- ml10
- doxepin
- zinc
- bcma-pd1-cart cell
- pronase
- autologous t cells
- 125-iodine
- [18f]f-resca-t4
- avm0703
- ibandronate
- cu64 trastuzumab
- it-101
- [18f]f-resca-rb14
- graviola
- [68ga]ga-nota-rnd20
- dexmedetomidine
- bvd-523
- [68ga]ga-nota-wwh347
- +15 more
Organizations
Organization Involved with Phase 4 Indications (15)
- National Cancer Institute (NCI)
- Zhengzhou University
- Osakidetza
- Temple University
- Abbott
- Luye Pharma
- Trinity College Dublin
- University of Chicago
- Pharmacosmos
- Henan Medical University
- University of Nottingham
- Jiao Tong University
- University of Lille
- St. James's Hospital, Dublin
- Chinese Academy of Medical Sciences
Organization Involved with Phase 3 Indications (108)
- Medical Research Council
- French Society of Radiation Oncology
- Seattle Genetics
- Taian Cancer Hospital
- Gruppo Oncologico del Nord-Ovest
- Canadian Cancer Trials Group
- Chinese University of Hong Kong
- University of California, Los Angeles
- Eurofarma Laboratorios S.A.
- Tianjin Medical University
- Federation Francophone de Cancerologie Digestive
- University of Adelaide
- North Central Cancer Treatment Group
- Shahai Hospital
- Moorgreen Hospital, Southampton
- Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
- Xinyang Central Hospital
- Fudan University
- Eastern Cooperative Oncology Group
- Huazhong University of Science and Technology
- Fujian Medical University
- Aventis
- Swiss Group for Clinical Cancer Research
- University of Vienna
- NRG Oncology
- Cantonal Hospital of St. Gallen
- Austrian Society Of Surgical Oncology
- University of Milan
- Japan Clinical Oncology Group
- Johnson and Johnson
- +78 more
Organization Involved with Phase 2 Indications (222)
- Bicycle Therapeutics
- SCRI Development Innovations
- Shanghai Junshi Bioscience Co.,Ltd.
- Arizona State University
- University of California, Irvine
- Hangzhou Cancer Hospital
- University of Michigan
- University of Angers
- Taizhou Hospital of Zhejiang Province
- Daiichi Sankyo
- The First People's Hospital of Lianyungang
- The Oregon Clinic
- Helmholtz Centre for Infection Research
- Anhui Kedgene Biotechnology Co.,Ltd
- Innovent Biologics (Suzhou) Co. Ltd.
- Institut de Cancerologie de l'Ouest Paul Papin
- Blokhin's Russian Cancer Research Center
- University of Texas, Galveston
- IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest
- Theradex
- Free University of Brussels
- Chao Family Comprehensive Cancer Center
- Karolinska Institute
- MedImmune
- CHU Besançon
- Hematology-Oncology Associates of Illinois
- Groupe Hospitalier Paris Saint Joseph
- Cancer Biotherapy Research Group
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Celgene
- +192 more
Organization Involved with Phase 1 Indications (44)
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- National Cancer Center, Japan
- University of Pennsylvania
- The EMMES Corporation
- Adaptimmune
- Dartmouth University
- Oncolys BioPharma Inc
- Free University of Amsterdam
- ShangHai HaiHe Pharmaceutical
- The Christie NHS Foundation Trust
- Athenex, Inc.
- Nordic Group BV
- Leap Therapeutics, Inc.
- AMAG Pharmaceuticals, Inc.
- Teikyo University
- Guangdong Xiangxue Precision Medical Technology Co., Ltd
- AIDS Malignancy Consortium
- Threshold Pharmaceuticals
- Japanese Foundation for Cancer Research
- Synta Pharmaceuticals Corp.
- Utrecht University
- Translational Drug Development
- Quadriga Biosciences, Inc.
- Novartis
- Kindai University
- ImmunoFrontier, Inc.
- Rhode Island Hospital
- Novotech
- MannKind Corp
- Cancer and Leukemia Group B (CALGB)
- +14 more
Organization Involved with Other Experimental Indications (11)
- Beijing Tide Pharmaceutical Co., Ltd
- University of Toyama
- North Wales Organisation for Randomised Trials in Health
- Instituto do Cancer do Estado de São Paulo
- Personal Improvement Computer Systems
- University of Colorado
- University of Colorado, Denver
- Technical University of Dresden
- Stemirna Therapeutics
- University of Gothenburg
- Erasmus University Rotterdam